Altshuler Shaham Ltd Buys New Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Altshuler Shaham Ltd bought a new stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,411,019 shares of the biotechnology company's stock, valued at approximately $2,082,000. Altshuler Shaham Ltd owned about 0.21% of OPKO Health as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Barclays PLC increased its holdings in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock worth $810,000 after acquiring an additional 329,870 shares during the period. Norges Bank bought a new stake in OPKO Health during the fourth quarter valued at $1,657,000. FMR LLC grew its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of OPKO Health in the 4th quarter valued at about $221,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of OPKO Health during the 4th quarter valued at about $102,000. Institutional investors own 64.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on OPK shares. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Finally, StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 67,434 shares of the stock in a transaction on Friday, February 28th. The stock was acquired at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the transaction, the chief executive officer now directly owns 213,301,448 shares of the company's stock, valued at $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 814,971 shares of company stock valued at $1,308,192 over the last 90 days. Company insiders own 49.69% of the company's stock.

OPKO Health Stock Up 4.7 %

Shares of NASDAQ:OPK traded up $0.07 on Tuesday, hitting $1.44. 1,015,733 shares of the company traded hands, compared to its average volume of 3,907,378. The company has a market cap of $963.67 million, a PE ratio of -7.55 and a beta of 1.78. The stock has a 50 day simple moving average of $1.66 and a 200-day simple moving average of $1.57. OPKO Health, Inc. has a 52 week low of $1.15 and a 52 week high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. As a group, research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.